Rituximab for the first-line treatment of stage III-IV follicular lymphoma (review of Technology Appraisal No. 110): Asystematic review and economic evaluation

Health Technology Assessment

Volumn 16, Issue 37, 2012, Pages

  Papaioannou, D ^a   Rafia, R ^a   Rathbone, J ^a   Stevenson, M ^a   Buckley Woods, H ^a   Stevens, J ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; MITOXANTRONE; PREDNISOLONE; RITUXIMAB; VINCRISTINE;

ARTICLE; BIOSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CINAHL; CLINICAL EFFECTIVENESS; COCHRANE LIBRARY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DATA BASE; DATA EXTRACTION; DRUG EFFICACY; DRUG RESPONSE; ECONOMIC EVALUATION; EMBASE; FOLLICULAR LYMPHOMA; FOLLOW UP; HUMAN; MEDLINE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; QUALITY ADJUSTED LIFE YEAR; REGISTER; SCISEARCH; STATISTICAL ANALYSIS; UNCERTAINTY;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHLORAMBUCIL; COST-BENEFIT ANALYSIS; CYCLOPHOSPHAMIDE; DOXORUBICIN; ENGLAND; FEMALE; HUMANS; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; MITOXANTRONE; MODELS, ECONOMIC; PREDNISOLONE; PREDNISONE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VINCRISTINE; WALES;

EID: 84867260620     PISSN: 13665278     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta16370     Document Type: Article

References (137)

1. Cancer Research UK. Cancer in the UK: July 2010. URL: http://info.cancerresearchuk.org/ prod_consump/groups/cr_common/@nre/@sta/documents/generalcontent/018070.pdf.
2. Cancer Research UK. Non-Hodgkin lymphoma (NHL) statistics-key facts. 2010. URL: http:// info.cancerresearchuk.org/cancerstats/types/nhl/.
3. Office for National Statistics (ONS). Cancer statistics registrations: registrations of cancer diagnosed in 2008. London: ONS; Newport; 2010.
4. Cancer Research UK. Non-Hodgkin lymphoma-UK mortality statistics. 2010. URL: http:// info.cancerresearchuk.org/cancerstats/types/nhl/mortality/.
5. Rohatiner AZ, Lister TA. The clinical course of follicular lymphoma. Best Pract Res Clin Haematol 2005;18:1-10.
6. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998;16:2780-95.
7. The Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 1997;89:3909-18.
8. Macmillan Cancer Support. Follicular lymphoma. London: Macmillan Cancer Support; 2009.
9. Cancer Research UK. Outlook for low grade lymphomas. London: Cancer Research UK; 2010. URL: www.cancerhelp.org.uk/type/non-hodgkins-lymphoma/treatment/ statistics-and-outlook-for-non-hodgkins-lymphoma#low.
10. Cancer Research UK. Non-Hodgkin lymphoma (NHL) statistics. Cancer statistics. 2010. URL: http://info.cancerresearchuk.org/cancerstats/types/nhl/incidence/.
11. Freytes CO, Burzynski JA. Lymphoma follicular. 2009. URL: http://emedicine.medscape.com/ article/203268-overview.
12. Tan D, Rosenberg SA, Levy R, Lavori R, Tibshiranio R, Hoppe RT, et al. Survival in follicular lymphoma. The Stanford Experience 1960-2003. Blood 2007;110:3428A.
13. Tan D, Rosenberg SA, Slava B, Levy R, Lavori R, Hoppe RT, et al. Closing the gap: a comparison of observed versus expected survival in follicular lymphoma at Stanford University from 1960-2003. J Clin Oncol 2008;26:S8535.
14. Fisher RI, LeBlanc M, Press OW, Maloney DG, Unger JM, Miller TP. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 2005;23:8447-52.
15. Liu Q, Fayad L, Cabanillas F, Hagemeister FB, Ayers GD, Hess M, et al. Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas MDAnderson Cancer Center. J Clin Oncol 2006;24:1582-9.
16. Welsh Cancer Intelligence & Surveillance Unit 2008.
17. National Cancer Intelligence Network (NCIN). One, five and ten year cancer prevalence. London: NCIN; 2010.
18. Cancer Research UK. Non-Hodgkin lymphoma-UK incidence statistics: trends over time. London: Cancer Research UK; 2010.
19. Dreyling M. Newly diagnosed and relapsed follicular lymphoma: ESMOClinical Practice Guidelines for diagnosis treatment and follow-up. Ann Oncol. 2010;21(Suppl. 5):181-3.
20. Fisher SG, Fisher RI. The epidemiology of non-Hodgkin's lymphoma. Oncogene 2004;23:6524-34.
21. Serraino D, Salamina G, Franceschi S, Dubois D, La Vecchia C, Brunet JB, et al. The epidemiology of AIDS-associated non-Hodgkin's lymphoma in the World Health Organization European Region. Br J Cancer 1992;66:912-16.
22. Ioachim HL. Neoplasms associated with immune deficiencies. Pathol Annu 1987;22:177-222.
23. Kersey JH, Shapiro RS, Filipovich AH. Relationship of immunodeficiency to lymphoid malignancy. Pediatr Infect Dis J 1988;7:S10-12.
24. Cartwright RA, McNally RJQ. Epidemiology of non-Hodgkin's lymphoma. Hematol Oncol 1994;3:1-34.
25. Filipovich AH, Mathur A, Kamat D, Shapiro RS. Primary immunodeficiencies: genetic risk factors for lymphoma. Cancer Res 1992;52:S5465-7.
26. Skarin AT, Dorfman DM. Non-Hodgkin's lymphomas: current classification and management. CA Cancer J Clin 1997;47:351-72.
27. British Committee for Standards in Haematology. Guidelines on diagnosis and therapy: nodal non-Hodgkin's lymphoma. London: BCSH; 2003.
28. Solal-Celigny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, et al. Follicular lymphoma international prognostic index. Blood 2004;104:1258-65.
29. Horning SJ. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 1993;20:75-88.
30. Gallagher CJ, Gregory WM, Jones AE, Stansfeld AG, Richards MA, Dhaliwal, et al. Follicular lymphoma: prognostic factors for response and survival. J Clin Oncol 1986;4:1470-80.
31. Al-Tourah AJ, Gill KK, Chhanabhai M, Hoskins PJ, Klasa RJ, Savage KJ, et al. Populationbased analysis of incidence and outcome of transformed non-Hodgkin's lymphoma. J Clin Oncol 2008;26:5165-9.
32. Olin RL, Kanetsky PA, Ten Have TR, Nasta SD, Schuster SJ, Andreadis C. Determinants of the optimal first-line therapy for follicular lymphoma: a decision analysis. Am J Hematol 2010;85:255-60.
33. Coiffier B. First-line treatment of follicular lymphoma in the era of monoclonal antibodies. Clin Adv Hematol Oncol 2005;3:484-91.
34. Carbone PP, Meier HS, Musshoff K, Smithers DW, Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 1971;31:1861.
35. Hiddemann W, Buske C, Dreyling M, Weigert O, Lenz G, Unterhalt M. Current management of follicular lymphomas. Br J Haematol 2007;136:191-202.
36. Knight C, Hind D, Brewer N, Abbott V. Rituximab (MabThera®) for aggressive non-Hodgkin's lymphoma: systematic review and economic evaluation. Health Technol Assess 2004;8(37).
37. Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, et al. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood 2007;110:695-708.
38. National Cancer Institute SEER Training. 2010. URL: http://training.seer.cancer.gov/ lymphoma/abstract-code-stage/morphology/formulation.html.
39. Lennert K, Feller AC, Diebold J, Paulli A, Le Torneau A. Histopathology of non-Hodgkin's lymphomas (based on the updated Kiel Classification), 2nd edn. New York, NY: Springer-Verlag; 1992.
40. Longo DL. What's the deal with follicular lymphomas? J Clin Oncol. 1993;11:202-8.
41. Ghielmini M, Rufibach K, Salles G, Leoncini-Franscini L, Leger-Falandry C, Cogliatti S, et al. Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 2005;16:1675-82.
42. Luminari S, Federico M. Prognosis of follicular lymphomas. Hematol Oncol 2006;24:64-72.
43. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55.
44. Decaudin D, Lepage E, Brousse N, Brice P, Harousseau JL, Belhadj K, et al. Low-grade stage III-IV follicular lymphoma: multivariate analysis of prognostic factors in 484 patients: a study of the groupe d'Etude des lymphomes de l'Adulte. J Clin Oncol 1999;17:2499-505.
45. Soubeyran P, Eghbali H, Bonchion F, Trojanic M, Richaudd P, Hoernia B. Low-grade follicular lymphomas: analysis of prognosis in a series of 281 patients. Eur J Cancer 1991;27:1606-13.
46. Morrison VA. Non-Hodgkin's lymphoma in the elderly. Part 1: overview and treatment of follicular lymphoma. Oncology 2007;21:1104-10.
47. Warnke RA, Kim H, Fuks Z, Dorfman RF. The coexistence of nodular and diffuse patterns in nodular non-Hodgkin's lymphomas: significance and clinicopathologic correlation. Cancer 1977;40:1229-33.
48. Hicks EE, Rappaport H, Winter WJ. Follicular lymphoma: a re-evaluation of its position in the scheme of malignant lymphoma based on a survey of 253 cases. Cancer 1956;9:792-821.
49. Ezdinli EZ, Costello WG, Kucuk O, Berard CW. Effect of the degree of nodularity on the survival of patients with nodular lymphomas. J Clin Oncol 1987;5:413-18.
50. Hu E, Weiss LM, Hoppe RT. Horning SJ. Follicular and diffuse mixed small-cleaved and large-cell lymphoma: a clinicopathologic study. J Clin Oncol 1985;3:1183-7.
51. Farinha P, Masoudi H, Skinnider BF, Shumansky K, Spinelli JJ, Gill K, et al. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood 2005;106:2169-74.
52. Medeiros LJ, Picker LJ, Gelb AB, Strickler JG, Brain SW, Weiss LM, et al. Numbers of host 'helper' T cells and proliferating cells predict survival in diffuse small-cell lymphomas. J Clin Oncol 1989;7:1009-17.
53. Strickler JG, Copenhaver CM, Rojas VA, Horning SJ, Warnke RA. Comparison of 'host cell infiltrates' in patients with follicular lymphoma with and without spontaneous regression. Am J Clin Pathol 1988;90:257-61.
54. Federico M, Vitolo U, Zinzani PL, Chisesi T, Clo V, Bellesi G, et al. Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases. Intergruppo Italiano Linfomi. Blood 2000;95:783-9.
55. Bastion Y, Berger F, Bryon PA, Felman PF, French M, Coiffier B. Follicular lymphomas: assessment of prognostic factors in 127 patients followed for 10 years. Ann Oncol 1991;2(Suppl. 2):123-9.
56. Romaguera JE, McLaughlin P, North L, Dixon D, Silvermintz KB, Garnsey LA, et al. Multivariate analysis of prognostic factors in stage IV follicular low-grade lymphoma: a risk model. J Clin Oncol 1991;9:762-9.
57. Lopez-Guillermo A, Montserrat E, Bosch F, Terol MJ, Campo E, Rozman C. Applicability of the International Index for Aggressive Lymphomas to patients with low-grade lymphoma. J Clin Oncol 1994;12:1343-8.
58. Solal-Celigny P, Cahu X, Cartron G. Follicular lymphoma prognostic factors in the modern era: what is clinically meaningful? Int J Hematol 2010;92:246-54.
59. Federico M, Bellei M, Marcheselli L, Luminari S, Lopez-Guillermo A, Vitolo U, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 2009;27:4555-62.
60. Morschhauser F, Dreyling M, Rohatiner A, Hagemeister F, Bischof Delaloye A. Rationale for consolidation to improve progression-free survival in patients with non-Hodgkin's lymphoma: a review of the evidence. Oncologist 2009;14(Suppl. 2):17-29.
61. Wake B, Hyde C, Bryan S, Barton P, Song F, Fry-Smith A. Rituximab as third-line treatment for refractory or recurrent Stage III or IV follicular non-Hodgkin's lymphoma: a systematic review and economic evaluation. Health Technol Assess 2002;6(3).
62. Roche. MabThera® (rituximab) for the first-line treatment of follicular non-Hodgkin's lymphoma: submission to the National Institute for Health and Clinical Excellence (NICE). London: NICE; 2010.
63. Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med 1984;311:1471-5.
64. Martinsson U, Glimelius B, Hagberg H, Sundstrom C. Primarily asymptomatic low-grade non-Hodgkin lymphomas: prediction of symptom-free survival and total survival. Eur J Haematol 1989;43:332-8.
65. Brice P, Bastion Y, Lepage E, Brousse N, Haioun C, Moreau P, et al. Comparison in lowtumor-burden follicular lymphomas between an initial no-treatment policy prednimustine or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 1997;15:1110-17.
66. Ardeshna KM, Smith P, Norton A, Hancock B, WHoskin PJ, MacLennan KA, et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet 2003;362:516-22.
67. Young RC, Longo DL, Glatstein E, Ihde DC, Jaffe ES, DeVita VT, Jr. The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment. Semin Hematol 1988;25:11-16.
68. National Institute for Health and Clinical Excellence (NICE). Rituximab for the treatment of follicular lymphoma (technology appraisal guidance 110). London: NICE; 2006.
69. Heinzelmann F, Ottinger H, Engelhard M, Soekler M, Bamberg M, Weinmann M. Advancedstage III/IV follicular lymphoma: treatment strategies for individual patients. Strahlenther Onkol 2010;186:247-54.
70. Hiddemann W. Rituximab maintenance therapy in follicular lymphoma comes of age. Leukemia Res 2006;30(Suppl. 1):S1-2.
71. Salles G, Seymour JF, Feugier P, Offner F, Lopez-Guillermo A, Bouabdallah R. Rituximab maintenance for 2 years in patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy (Abstract 8004). ASCO Annual Meeting, 4-8 June 2010 Chicago, IL USA.
72. Rohatiner A, Gregory WM, Peterson E, Borden P, Solal-Celigny P, Hagenbeek A. Meta-Analysis to evaluate the role of interferon in follicular lymphoma. J Clin Oncol 2005;23:2215-23.
73. National Institute for Health and Clinical Excellence (NICE). Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma (review of technology appraisal guidance 137). London: NICE; 2008.
74. van Oers MH, Van Glabbeke M, Giurgea L, Klasa R, Marcus RE, Wolf M. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: longterm outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol 2010;28:2853-8.
75. van Oers MH, Klasa R, Marcus R, Wolf H, Kimby E, Gascoyne RD, et al Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 2006;108:3295-304.
76. British Committee for Standards in Haematology (BCSH). Best practice in lymphoma diagnosis and reporting. London: BCSH; 2010.
77. British Committee for Standards in Haematology (BCSH). Best practice in lymphoma diagnosis and reporting: specific disease appendix. London: BCSH; 2010.
78. Rummel M, Niederle N, Maschmeyer G, Banat A, von Gruenhagen U, Losem C, et al. Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular indolent mantle cell lymphomas: final results of a randomized phase III Study of the StiL (Study Group Indolent Lymphomas, Germany). 2009. 51st ASH Annual Meeting and Exposition, New Orleans, LA, USA. 5-8 December 2009.
79. Multicentric Study. Three Randomized Arms (R-CVP vs R-CHOP vs R-FM) for Patients With Stage II-IV Follicular Lymphoma. URL: http://clinicaltrials.gov/ct2/show/ NCT00774826.
80. First-Line R-CVP vs R-CHOP. Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance. (PLRG4). URL: http://clinicaltrials.gov/ct2/show/NCT00801281.
81. Alkylator Combination In Follicular lymphoma Immuno-Chemotherapy for Older patients: a phase III comparison of first-line R-CVP versus R-FC (previous acronym: RiCH FLO). URL: http://public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=6968.
82. Siddhartha G, Vijay P. R-CHOP versus R-CVP in the treatment of follicular lymphoma: a meta-analysis and critical appraisal of current literature. J Hematol Oncol 2009;2:14.
83. National Institute for Health and Clinical Excellence (NICE). Rituximab for the treatment of follicular lymphoma: NICE technology appraisal guidance 110. London: NICE; 2006.
84. Anderson KC, Bates MP, Slaughenhoupt BL, Pinkus GS, Schlossman SF, Nadler LM. Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood 1984;63:1424-33.
85. European Medicines Agency (EMA). MabThera: European Public Assessment Report (EPAR)-Product information: Annex I-summary of product characteristics. London: EMA; 2011.
86. British Medical Association and Royal Pharmaceutical Society of Great Britain. British national formulary. No. 61, March 2011. London: BMA and RPS; 2011.
87. British Committee for Standards in Haematology (BCSH). Follicular lymphoma. London: BCSH; 2011.
88. Moher D, Liberati A, Tetzlaff J, Altman DG. The PRISMA Group Preferred Reporting Items for Systematic Reviews and Meta-Analyses The PRISMA Statement. J Clin Epidemiol 2009;62:1006-12.
89. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCISponsored International Working Group. J Clin Oncol 1999;17:1244-53.
90. Centre for Reviews and Dissemination (CRD). Centre for Reviews and Dissemination Systematic reviews: CRD's guidance for undertaking reviews in health care. York: CRD; 2009.
91. Buske C, Hoster E, Dreyling M, Forstpointner R, Kneba M, Schmitz N, et al. Rituximab in combination with CHOP in patients with follicular lymphoma: analysis of treatment outcome of 552 patients treated in a randomized trial of the German Low Grade Lymphoma Study Group (GLSG) after a follow up of 58 months. Abstract no. 2599. Blood 2008;112:901.
92. Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide doxorubicin vincristine prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005;106:3725-32.
93. Herold M, Haas A, Srock S, Neser S, Al-Ali KH, Neubauer A, et al. East German Study Group Hematology and Oncology Study. Rituximab added to first-line mitoxantrone chlorambucil prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol 2007;25:1986-92.
94. Salles G, Mounier N, de Guibert S, Morschhauser F, Doyen C, Rossi JF, et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMSFL2000 study. Blood 2008;112:4824-31.
95. Marcus R, Imrie K, Solal-Celigny P, Catalano JV, Dmoszynska A, Raposo JC, et al. Phase III study of R-CVP compared with cyclophosphamide vincristine prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008;26:4579-86.
96. Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005;105:1417-23.
97. National Institute for Health and Clinical Excellence (NICE). Guide to the methods of technology appraisal. London: NICE; 2008.
98. A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL). URL: http://clinicaltrials.gov/ct2/show/NCT01144364.
99. BNLIRCT of MCD vs FMD in follicular NHL. URL: http://public.ukcrn.org.uk/search/ StudyDetail.aspx?StudyID=908.
100. National Cancer Institute (NCI). Common Toxicity Criteria (CTC). London: NCI; 2011.
101. World Health Organization (WHO) Handbook for reporting results of cancer treatment. WHO offset publication No. 48. Neoplasm 1980;20:37-46.
102. Solal-Celigny P, Imrie K, Belch A, Robinson K-S, Cunningham D, Rueda A, et al. (Rituximab) plus CVP chemotherapy for first-line treatment of stage III/IV follicular non-Hodgkin's lymphoma (NHL): confirmed efficacy with longer follow-up. Blood 2005;106:106A.
103. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998;17:2815-34.
104. European Medicines Agency (EMA). Assessment report for MabThera: international nonproprietary name/common name: rituximab procedure no EMEA/H/C/000165/II/0053. London: EMA; 2008.
105. Buske C, Hoster E. The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate-or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood 2006;108:1504-8.
106. Higgins JPT, Green S (editors). Cochrane handbook for systematic reviews of interventions, version 5.0.2 (updated September 2009). The Cochrane Collaboration, 2009. URL: www. cochrane-handbook.org.
107. Brundage MD, Pater JL, Zee B. Assessing the reliability of two toxicity scales: implication for interpreting toxicity data. J Nat Cancer Inst 1993;85:1148.
108. Moher D, Schulz KF, Altman DG, for the Consort Group. The CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomized trials. Ann Intern Med 2001;134:657-62.
109. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ 1996;313:275-83.
110. Eddy DM. Technology Assessment: The Role of Mathematical Modeling. In Assessing Medical Technologies. Washington, DC: National Academy Press; 1985.
111. Ray JA, Carr E, Lewis G, Marcus R. An evaluation of the cost-effectiveness of rituximab in combination with chemotherapy for the first-line treatment of follicular non-Hodgkin's lymphoma in the UK. Value Health 2010;13:346-57.
112. Dundar Y, Hounsome J, McLeod C, Bagust A, Boland A, Davis H, et al. Rituximab for the first line treatment of stage III-IV follicular non-Hodgkin's lymphoma. London: NICE; 2006.
113. Dundar Y, Bagust A, Hounsome J, McLeod C, Boland A, Davis H, et al. Rituximab for the first-line treatment of stage III/IV follicular non-Hodgkin's lymphoma. Health Technol Assess 2009;13(Suppl. 1):23-8.
114. Gomez J, Rios E, Rubio C, Castro Gomez A, Varela C. Pharmacoeconomic analysis of adding rituximab to chemotherapy as first line treatment for patients with advanced follicular lymphoma. Pharmacoeconomics 2010;7:55-67.
115. Hornberger J, Reyes C, Lubeck D, Valente N, Hornberger J, Reyes C, et al. Economic evaluation of rituximab plus cyclophosphamide vincristine and prednisolone for advanced follicular lymphoma. Leuk Lymphoma 2008;49:227-36.
116. Scottish and Newcastle Lymphoma Group (SNLG). Database analysis (Roche data on file). 2004.
117. Swenson WT, Wooldridge JE, Lynch CF, Forman-Hoffman VL, Chrischilles E, Link BK. Improved survival of follicular lymphoma patients in the United States. J Clin Oncol 2005;23:5019-26.
118. Wild D, Pettengell R, Lewis G. Utility elicitation in patients with follicular lymphoma. 2006. International Society for Pharmaeconomics and Outcomes Research (ISPOR), 9th Annual European Congress, Copenhagen, Denmark, 28-31 October 2006.
119. Wild D, Pettengell R, Lewis G. Utility elicitation in patients with follicular lymphoma. Unpublished report by Oxford Outcomes prepared for Roche UK 2005.
120. Tolley K, Morgan G, Cartwright R, Williams R. Economic aspects of non-Hodgkin's lymphoma. London: Office of Health Economics; 1998.
121. Guadagnolo BA, Punglia RS, Kuntz KM, Mauch PM, Ng AK. Cost-effectiveness analysis of computerized tomography in the routine follow-up of patients after primary treatment for Hodgkin's disease. J Clin Oncol 2006;24:4116-22.
122. ASP. Drug Pricing Files. Center for Medicaid and Medicare Services. 2006.
123. Hoover D, Crystal S, Kumar R, Sambamoorthi U, Cantor J. Medical expenditures during the last year of life: findings from the 1992-1996 Medicare current beneficiary survey. Health Serv Res 2002;37:1625-42.
124. Roche. Rituximab for the first line maintenance treatment of follicular non-Hodgkin's lymphoma: Roche submission to the National Institute for Health and Clinical Excellence. 2010.
125. Ward S, Salzano S, Sampson F, Cowan J. Guidance on Cancer Services: Improving Supportive and Palliative Care for Adults with CANCER. Economic Review. NICE: London; 2004. URL: http://guidance.nice.org.uk/nicemedia/live/10893/28817/28817.pdf.
126. Greenhalgh J, Bagust A, Boland A, Blundell M, Oyee J, Dundar Y, et al. Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma: a single technology appraisal. 2012; in press.
127. National Institute for Health and Clinical Excellence (NICE). Rituximab for the maintenance treatment of follicular non-Hodgkin's lymphoma following response to first-line chemotherapy. London: NICE; 2011.
128. Johnston A, Bouafia-Sauvy F, Broussais-Guillaumot F, Michallet AS, Traulle C, Salles G, et al. Re-treatment with rituximab in 178 patients with relapsed and refractory B-cell lymphomas: a single instiution case control study. Leuk Lymphoma 2010;51:399-405.
129. Coiffier B, Bouafia-Sauvy F, Thieblemont C, Hequet O, Arnaud P, Dumontet C, et al. Rituximab re-treatment in B-cell lymphoma patients: efficacy and toxicity in 59 patients terated in one center. Blood 2002;100:1390.
130. Borgerding A, Hasenkamp J, Glass B, Wulf G, Trumper L. Rituximab retherapy in patients with relapsed aggressive B cell and mantle cell lymphoma. Ann Hematol 2010;89:283-9.
131. Martin A, Conde E, Arnan M, Canales MA, Deben G, Sancho JM, et al. DR-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. AGEL/TAMO study. Haematologica 2008;93:1829-36.
132. Weide R, Hess G, Koppler H, Heymanns J, Thomalla J, Aldaoud A, et al. High antilymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter
133. Gao G, Liang X, Jiang J, Zhou X, Huang R, Chu Z, et al. A systematic review and metaanalysis of immunochemotherapy with rituximab for B-cell non-Hodgkin's lymphoma. Acta Oncol 2010;49:3-12.
134. Schulz H, Bohlius J, Skoetz N, Trelle S, Kober T, Reiser M, et al. Chemotherapy plus rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma. Cochrane Database Syst Rev 2007;4: CD003805. DOI: 10.1002/14651858.CD003805.pub2. 2007.
135. Schulz H, Bohlius J, Trelle S, Skoetz N, Reiser M, Kober T, et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma. J Nat Cancer Inst 2007;99:706-14.
136. Office for National Statistics (ONS). Mid year population estimates 2008. London: ONS; 2010.
137. Cancer Research UK. Performance status. 2011. URL: http://cancerhelp.cancerresearchuk.org/about-cancer/cancer-questions/performance-status (accessed 28 June 2012).